BriaCell’s Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3

• BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpoint
• Highly expressed on the cell surfaces of both tumor and immune cells, B7-H3 is a promising anti-cancer target for drugs both effecting cancer cells and blocking immune checkpoint activity
• BriaPro expects to advance anti-B7-H3 antibodies into development of proprietary antibody-drug conjugates, T cell engagers, and targeted immune checkpoint inhibitors with potential applications in multiple cancer indications
• BriaPro has filed US patent applications for this technology

Excerpt from the Press Release:

PHILADELPHIA and VANCOUVER, British Columbia, April 10, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), are pleased to announce that BriaPro is developing novel, high affinity antibodies to B7-H3, a key player in cancer progression, using molecular modeling techniques. BriaPro has filed provisional US patent applications for the corresponding technology and plans on filing an international patent application under the Patent Cooperation Treaty (PCT).

As both an immune checkpoint molecule that regulates T cell activity and a cell surface molecule expressed on many types of cancer cells, B7-H3 is a promising drug target. BriaPro plans on developing anti-B7-H3 antibodies for multiple cancer indications and plans to incorporate them into its Bria-TILsRx™ platform—a proprietary antibody platform designed to redirect and activate T cells within the tumor microenvironment. This platform integrates both T cell engagers, which promote T cell-mediated tumor killing, and tumor-targeted immune checkpoint modulators, which selectively block inhibitory signals on tumor infiltrating lymphocytes (TILs) to enhance their anti-tumor activity.

“B7-H3 is overexpressed in a broad range of solid tumors (including prostate, lung, breast, pancreatic, and ovarian cancers) while showing limited expression in normal tissues. This makes it an ideal target to selectively activate tumor infiltrating lymphocytes and drive potentially potent anti-tumor responses with reduced risk of off-target toxicity,” stated Miguel Lopez-Lago, PhD, BriaCell and BriaPro CSO.

Click the button below to read the entire Press Release:

Continue Reading The Press Release